Evidence map›Paper›PMID 26951635›Full record

ArticleCirculation research2016

Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk.

Patrick R Lawler, Akintunde O Akinkuolie, Paulette D Chandler, M Vinayaga Moorthy, Martin J Vandenburgh, Debra A Schaumberg, I-Min Lee, Robert J Glynn, Paul M Ridker, Julie E Buring and 1 more

2 registry-linked trialsAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 71 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000479 phase3completednot on this map

Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women

TypeinterventionalSponsorBrigham and Women's HospitalRan1992 to 2005Enrolled39,876ConditionsCardiovascular Diseases, Cerebrovascular Disorders, Coronary Disease, Heart DiseasesArmsAspirin, Vitamin E, Placebo
NCT00239681 phase3terminatednot on this map

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR®) 20 mg in the Prevention of Cardiovascular Events Among Subjects With Low Levels of Low Density Lipoprotein(LDL) Cholesterol & Elevated Levels of C-Reactive Protein

TypeinterventionalSponsorAstraZenecaRan2003 to 2008Enrolled17,802ConditionsElevated High-sensitivity C-Reactive Protein (hsCRP)ArmsRosuvastatin, Placebo
3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Association of Glycoprotein Acetylation With Carotid-Femoral Pulse Wave Velocity in Patients Receiving Maintenance Hemodialysis.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Patrick R LawlerFrom the Center for Lipid Metabolomics (P.R.L., A.O.A., S.M.), the Cardiovascular Division (P.R.L., P.MR., S.M.) and Division of Preventive Medicine (P.R.L., A.O.A., P.D.C., M.V.M., M.J.V., I.-M.L., R.J.G., P.MR., J.E.B., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Harvard Chan School of Public Health, Boston, MA (P.R.L., I-M.L., R.J.G., P.MR., J.E.B.), and Department of Ophthalmology and Visual Sciences, Center for Translational Medicine, John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City (D.A.S.).
Akintunde O AkinkuolieFrom the Center for Lipid Metabolomics (P.R.L., A.O.A., S.M.), the Cardiovascular Division (P.R.L., P.MR., S.M.) and Division of Preventive Medicine (P.R.L., A.O.A., P.D.C., M.V.M., M.J.V., I.-M.L., R.J.G., P.MR., J.E.B., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Harvard Chan School of Public Health, Boston, MA (P.R.L., I-M.L., R.J.G., P.MR., J.E.B.), and Department of Ophthalmology and Visual Sciences, Center for Translational Medicine, John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City (D.A.S.).
Paulette D ChandlerFrom the Center for Lipid Metabolomics (P.R.L., A.O.A., S.M.), the Cardiovascular Division (P.R.L., P.MR., S.M.) and Division of Preventive Medicine (P.R.L., A.O.A., P.D.C., M.V.M., M.J.V., I.-M.L., R.J.G., P.MR., J.E.B., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Harvard Chan School of Public Health, Boston, MA (P.R.L., I-M.L., R.J.G., P.MR., J.E.B.), and Department of Ophthalmology and Visual Sciences, Center for Translational Medicine, John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City (D.A.S.).
M Vinayaga MoorthyFrom the Center for Lipid Metabolomics (P.R.L., A.O.A., S.M.), the Cardiovascular Division (P.R.L., P.MR., S.M.) and Division of Preventive Medicine (P.R.L., A.O.A., P.D.C., M.V.M., M.J.V., I.-M.L., R.J.G., P.MR., J.E.B., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Harvard Chan School of Public Health, Boston, MA (P.R.L., I-M.L., R.J.G., P.MR., J.E.B.), and Department of Ophthalmology and Visual Sciences, Center for Translational Medicine, John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City (D.A.S.).
Martin J VandenburghFrom the Center for Lipid Metabolomics (P.R.L., A.O.A., S.M.), the Cardiovascular Division (P.R.L., P.MR., S.M.) and Division of Preventive Medicine (P.R.L., A.O.A., P.D.C., M.V.M., M.J.V., I.-M.L., R.J.G., P.MR., J.E.B., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Harvard Chan School of Public Health, Boston, MA (P.R.L., I-M.L., R.J.G., P.MR., J.E.B.), and Department of Ophthalmology and Visual Sciences, Center for Translational Medicine, John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City (D.A.S.).
Debra A SchaumbergFrom the Center for Lipid Metabolomics (P.R.L., A.O.A., S.M.), the Cardiovascular Division (P.R.L., P.MR., S.M.) and Division of Preventive Medicine (P.R.L., A.O.A., P.D.C., M.V.M., M.J.V., I.-M.L., R.J.G., P.MR., J.E.B., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Harvard Chan School of Public Health, Boston, MA (P.R.L., I-M.L., R.J.G., P.MR., J.E.B.), and Department of Ophthalmology and Visual Sciences, Center for Translational Medicine, John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City (D.A.S.).
I-Min LeeFrom the Center for Lipid Metabolomics (P.R.L., A.O.A., S.M.), the Cardiovascular Division (P.R.L., P.MR., S.M.) and Division of Preventive Medicine (P.R.L., A.O.A., P.D.C., M.V.M., M.J.V., I.-M.L., R.J.G., P.MR., J.E.B., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Harvard Chan School of Public Health, Boston, MA (P.R.L., I-M.L., R.J.G., P.MR., J.E.B.), and Department of Ophthalmology and Visual Sciences, Center for Translational Medicine, John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City (D.A.S.).
Robert J GlynnFrom the Center for Lipid Metabolomics (P.R.L., A.O.A., S.M.), the Cardiovascular Division (P.R.L., P.MR., S.M.) and Division of Preventive Medicine (P.R.L., A.O.A., P.D.C., M.V.M., M.J.V., I.-M.L., R.J.G., P.MR., J.E.B., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Harvard Chan School of Public Health, Boston, MA (P.R.L., I-M.L., R.J.G., P.MR., J.E.B.), and Department of Ophthalmology and Visual Sciences, Center for Translational Medicine, John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City (D.A.S.).
Paul M RidkerFrom the Center for Lipid Metabolomics (P.R.L., A.O.A., S.M.), the Cardiovascular Division (P.R.L., P.MR., S.M.) and Division of Preventive Medicine (P.R.L., A.O.A., P.D.C., M.V.M., M.J.V., I.-M.L., R.J.G., P.MR., J.E.B., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Harvard Chan School of Public Health, Boston, MA (P.R.L., I-M.L., R.J.G., P.MR., J.E.B.), and Department of Ophthalmology and Visual Sciences, Center for Translational Medicine, John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City (D.A.S.).
Julie E BuringFrom the Center for Lipid Metabolomics (P.R.L., A.O.A., S.M.), the Cardiovascular Division (P.R.L., P.MR., S.M.) and Division of Preventive Medicine (P.R.L., A.O.A., P.D.C., M.V.M., M.J.V., I.-M.L., R.J.G., P.MR., J.E.B., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Harvard Chan School of Public Health, Boston, MA (P.R.L., I-M.L., R.J.G., P.MR., J.E.B.), and Department of Ophthalmology and Visual Sciences, Center for Translational Medicine, John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City (D.A.S.).
Samia MoraFrom the Center for Lipid Metabolomics (P.R.L., A.O.A., S.M.), the Cardiovascular Division (P.R.L., P.MR., S.M.) and Division of Preventive Medicine (P.R.L., A.O.A., P.D.C., M.V.M., M.J.V., I.-M.L., R.J.G., P.MR., J.E.B., S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Harvard Chan School of Public Health, Boston, MA (P.R.L., I-M.L., R.J.G., P.MR., J.E.B.), and Department of Ophthalmology and Visual Sciences, Center for Translational Medicine, John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City (D.A.S.). smora@partners.org.

Funding

Women's Health Study: Continued Follow-upR01CA047988 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 1991 to 2014
$28.2M
Training Program in the Epidemiology of CVDT32HL007575 · NHLBI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BURING, JULIE E., RIDKER, PAUL M. · 1985 to 2019
$5.0M
Women's Health Study: Continued Follow-UpR01HL080467 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E. · 2005 to 2010
$4.5M
The Women's Health Study: Infrastructure Support for Continued Cohort Follow-upUM1CA182913 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 2014 to 2018
$4.0M
Total plasma and IgG glycomes, statin therapy and ASCVD eventsR01HL117861 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MORA, SAMIA · 2013 to 2022
$3.8M
TRIAL OF VITAMIN E, BETA-CAROTENE &ASPRIN IN WOMENR01HL043851 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1991 to 2000
$1.6M
The Women's Health Study: Addition of New Data to Maximize its Research ImpactRC1HL099355 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E. · 2009 to 2010
$992k
NCI NIH HHS CA047988NCI NIH HHS R01 CA047988NCI NIH HHS UM1 CA182913NHLBI NIH HHS HL080467NHLBI NIH HHS HL099355NHLBI NIH HHS R01 HL043851NHLBI NIH HHS R01 HL080467NHLBI NIH HHS R01 HL117861NHLBI NIH HHS R01HL117861NHLBI NIH HHS RC1 HL099355NHLBI NIH HHS T32 HL007575
6 · The paper itself

Abstract

rationaleCirculating glycoprotein N-acetyl glucosamine residues have recently been associated with incident cardiovascular disease and diabetes mellitus.

objectiveUsing a plasma glycan biosignature (GlycA) to identify circulating N-acetyl glycan groups, we examined the longitudinal association between GlycA and mortality among initially healthy individuals. METHODS AND

resultsWe quantified GlycA by 400 MHz (1)H nuclear magnetic resonance spectroscopy in 27,524 participants in the Women's Health Study (NCT00000479). The primary outcome was all-cause mortality. We replicated the findings in an independent cohort of 12,527 individuals in the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial (NCT00239681). We also undertook secondary examination of cardiovascular disease and cancer mortality in the Women's Health Study. In the Women's Health Study, during 524,515 person-years of follow-up (median, 20.5 years), there were 3523 deaths. Risk factor-adjusted multivariable Cox proportional hazard ratio (95% confidence interval) per SD increment in GlycA for all-cause mortality was significantly increased at 5 years (1.21 [1.06-1.40]) and during maximal follow-up (1.14 [1.09-1.16]). Similar risk for all-cause mortality was observed in the replication cohort (1.33 [1.21-1.45]). In the Women's Health Study, risk of cardiovascular disease mortality was increased at 5 years (1.43 [1.05-1.95]) and during maximal follow-up (1.15 [1.04-1.26]) and of cancer mortality at 5 years (1.23 [1.02-1.47]) and during maximal follow-up (1.08 [1.01-1.16]). Examination of correlations and mortality associations adjusted for high-sensitivity C-reactive protein, fibrinogen, and intercellular adhesion molecule-1, suggested that GlycA reflects summative risk related to multiple pathways of systemic inflammation.

conclusionsAmong initially healthy individuals, elevated baseline circulating glycoprotein N-acetyl methyl groups were associated with longitudinal risk of all-cause, cardiovascular, and cancer mortality.

Indexed as

MortalityAcetylgalactosamineAcetylglucosamineAcute-Phase ProteinsAgedBiomarkersBlood ProteinsCardiovascular DiseasesCause of DeathC-Reactive ProteinFemaleFollow-Up StudiesGlycoproteinsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInflammationAcetylgalactosamineAcetylglucosamineAcute-Phase ProteinsBiomarkersBlood ProteinsC-Reactive ProteinGlycoproteinsHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsPolysaccharidescardiovascular diseasesglycoproteinsmagnetic resonance spectroscopymetabolomicsmortalityneoplasmsrisk factors

Identifiers

PMID26951635
PMCPMC4836171

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.